Boston Scientific Corporation $BSX Shares Bought by Qsemble Capital Management LP

Posted by on May 16th, 2026

Qsemble Capital Management LP boosted its position in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 64.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 127,966 shares of the medical equipment provider’s stock after acquiring an additional 50,313 shares during the quarter. Boston Scientific comprises about 1.0% of Qsemble Capital Management LP’s portfolio, making the stock its 6th largest holding. Qsemble Capital Management LP’s holdings in Boston Scientific were worth $12,202,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Boston Scientific by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after buying an additional 1,115,337 shares during the last quarter. Rathbones Group PLC raised its stake in shares of Boston Scientific by 20.9% during the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after buying an additional 477,680 shares during the last quarter. Tounjian Advisory Partners LLC purchased a new position in shares of Boston Scientific during the 4th quarter valued at about $1,477,000. Kepler Cheuvreux Suisse SA purchased a new position in shares of Boston Scientific during the 3rd quarter valued at about $26,955,000. Finally, Waycross Partners LLC purchased a new position in shares of Boston Scientific during the 4th quarter valued at about $2,384,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $52.67 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a twelve month low of $52.52 and a twelve month high of $109.50. The business has a 50-day moving average price of $63.40 and a 200 day moving average price of $81.79. The firm has a market cap of $78.27 billion, a PE ratio of 22.04, a P/E/G ratio of 0.98 and a beta of 0.62.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the previous year, the business earned $0.75 EPS. Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the subject of a number of recent research reports. Raymond James Financial reiterated an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. Mizuho reduced their price objective on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Needham & Company LLC reduced their price objective on Boston Scientific from $97.00 to $77.00 and set a “buy” rating for the company in a research note on Thursday, April 23rd. Finally, National Bank Financial set a $115.00 price target on Boston Scientific in a research note on Monday, February 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $93.91.

Check Out Our Latest Report on BSX

About Boston Scientific

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.

Read More

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.